33 trials changed in the last 30 days: 0 stopped, 10 with notable changes, 23 with minor changes only.
Primary and study completion pushed from Aug 2027 to May 2028
Also in this update: Enrollment increased: 121 → 142 participants; Trial sites reduced: 23 → 20 locations
AbbViePhase 1 NCT07232004 Registry history of NCT07232004 on ClinicalTrials.gov (opens the registry)
Primary and study completion pushed from May 3, 2027 to Dec 31, 2027
UCB Biopharma SRLPhase 1 NCT06888193 Registry history of NCT06888193 on ClinicalTrials.gov (opens the registry)
Primary completion pushed from Jun 1, 2026 to Jul 1, 2027
Also in this update: Study completion pushed from Sep 1, 2026 to Sep 1, 2028
Centre Hospitalier Universitaire de NiceNot applicable NCT05399433 Registry history of NCT05399433 on ClinicalTrials.gov (opens the registry)
Primary endpoint(s) modified
Also in this update: Results posted: Sep 30, 2026; Trial completed
Terrence A BarrettNot applicable NCT04504136 Registry history of NCT04504136 on ClinicalTrials.gov (opens the registry)
Enrollment reduced: 5 → 3 participants
Xijing HospitalNot applicable NCT07780929 Registry history of NCT07780929 on ClinicalTrials.gov (opens the registry)
Phase changed: not applicable → not specified
Bursa Yuksek Ihtisas Training and Research HospitalNot specified NCT07858591 Registry history of NCT07858591 on ClinicalTrials.gov (opens the registry)
Recruitment opened
Novartis PharmaceuticalsPhase 2 NCT07801495 Registry history of NCT07801495 on ClinicalTrials.gov (opens the registry)
Recruitment opened
Fujian Shengdi Pharmaceutical Co., Ltd.Phase 1 NCT07802964 Registry history of NCT07802964 on ClinicalTrials.gov (opens the registry)
Recruitment opened
Modern Research Associates, PLLCPhase 4 NCT07725822 Registry history of NCT07725822 on ClinicalTrials.gov (opens the registry)
Start date pushed from Nov 16, 2026 to Jan 1, 2027
Northwestern UniversityNot applicable NCT07865390 Registry history of NCT07865390 on ClinicalTrials.gov (opens the registry)
Enrollment closed, study ongoing
Oruka Therapeutics, Inc.Phase 2 NCT07474792 Registry history of NCT07474792 on ClinicalTrials.gov (opens the registry)
Enrollment closed, study ongoing
Also in this update: Trial sites reduced: 123 → 120 locations
TakedaPhase 3 NCT06671496 Registry history of NCT06671496 on ClinicalTrials.gov (opens the registry)
Enrollment closed, study ongoing
Also in this update: Study completion pushed from Jan 15, 2027 to Sep 13, 2027
MoonLake Immunotherapeutics AGPhase 3 NCT06641089 Registry history of NCT06641089 on ClinicalTrials.gov (opens the registry)
Primary completion pushed from Sep 5, 2024 to Oct 10, 2024
Bristol-Myers SquibbPhase 3 NCT04908202 Registry history of NCT04908202 on ClinicalTrials.gov (opens the registry)
Trial completed
Also in this update: Enrollment increased: 17 → 21 participants
AmgenPhase 3 NCT05565560 Registry history of NCT05565560 on ClinicalTrials.gov (opens the registry)
Trial completed
Also in this update: Study completion date changed from estimate of Sep 30, 2025 to Nov 26, 2025
AO GENERIUMPhase 3 NCT06488664 Registry history of NCT06488664 on ClinicalTrials.gov (opens the registry)
Trial completed
Also in this update: Final enrollment: 160 participants (planned 120)
Clin4allNot specified NCT05938361 Registry history of NCT05938361 on ClinicalTrials.gov (opens the registry)
Enrollment closed, study ongoing
Also in this update: Primary completion pushed from May 2026 to Nov 2026; Study completion pushed from Jun 2026 to Apr 2027
Bausch Health Americas, Inc.Phase 4 NCT03987763 Registry history of NCT03987763 on ClinicalTrials.gov (opens the registry)
Enrollment closed, study ongoing
Also in this update: Primary and study completion moved earlier from Nov 2027 to Aug 2027
Eli Lilly and CompanyPhase 4 NCT06864026 Registry history of NCT06864026 on ClinicalTrials.gov (opens the registry)
Trial completed
Also in this update: Final enrollment: 55 participants (planned 94); Trial arms changed: 9 → 7
Ascletis Pharma (China) Co., LimitedPhase 1 NCT07024602 Registry history of NCT07024602 on ClinicalTrials.gov (opens the registry)
Trial completed
Also in this update: Primary completion date changed from estimate of Dec 1, 2026 to Jun 1, 2026
Cairo UniversityPhase 4 NCT07432815 Registry history of NCT07432815 on ClinicalTrials.gov (opens the registry)
Trial status changed: Not Yet Recruiting → Active, Not Recruiting
Also in this update: Primary completion pushed from Jan 2027 to Apr 2027; Study completion pushed from Mar 2027 to Sep 2027
Hexsel Dermatology ClinicPhase 2 NCT07313072 Registry history of NCT07313072 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 408 → 411 locations
And 1 more change in the last 30 days
Bristol-Myers SquibbPhase 3 NCT07116967 Registry history of NCT07116967 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 4 → 7 locations
Novartis PharmaceuticalsNot specified NCT07683065 Registry history of NCT07683065 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 4 → 10 locations
Vanda PharmaceuticalsPhase 3 NCT07362017 Registry history of NCT07362017 on ClinicalTrials.gov (opens the registry)
Primary completion date changed from estimate of Feb 4, 2027 to May 28, 2026
MoonLake Immunotherapeutics AGPhase 3 NCT06641076 Registry history of NCT06641076 on ClinicalTrials.gov (opens the registry)
Study completion pushed from Mar 31, 2026 to Dec 2026
Bausch Health Americas, Inc.Not specified NCT05132231 Registry history of NCT05132231 on ClinicalTrials.gov (opens the registry)
Registry marked status Unknown (sponsor has not verified the record since Sep 2024); last known: Recruiting
Shanghai Huaota Biopharmaceutical Co., Ltd.Phase 2/3 NCT06477536 Registry history of NCT06477536 on ClinicalTrials.gov (opens the registry)
Changed
Registry marked status Unknown (sponsor has not verified the record since Sep 2024); last known: Not Yet Recruiting
Newsoara Biopharma Co., Ltd.Not applicable NCT06584058 Registry history of NCT06584058 on ClinicalTrials.gov (opens the registry)
Changed
Registry marked status Unknown (sponsor has not verified the record since Sep 2024); last known: Active, Not Recruiting
Services Institute of Medical Sciences, PakistanPhase 1/2 NCT06591273 Registry history of NCT06591273 on ClinicalTrials.gov (opens the registry)
Changed
Registry marked status Unknown (sponsor has not verified the record since Sep 2024); last known: Recruiting
I.R.C.C.S Ospedale Galeazzi-Sant'AmbrogioNot specified NCT06630715 Registry history of NCT06630715 on ClinicalTrials.gov (opens the registry)
Changed
Registry marked status Unknown (sponsor has not verified the record since Sep 2024); last known: Recruiting
Global Healthy Living FoundationNot specified NCT05652608 Registry history of NCT05652608 on ClinicalTrials.gov (opens the registry)
Changed
Registry marked status Unknown (sponsor has not verified the record since Sep 2024); last known: Recruiting
University Hospital, GhentNot applicable NCT04080635 Registry history of NCT04080635 on ClinicalTrials.gov (opens the registry)
Changed
Registry verification sweep
Changed
| First posted | Trial | Sponsor | Phase |
|---|---|---|---|
| 2026-10-05 | NCT07858591 Retinal Capillary Vessel Density and Foveal Avascular Zone Size in Patients With… | Bursa Yuksek Ihtisas Training and Research Hospital new | |
| 2026-09-30 | NCT07849101 Ceramol PSOR Cream as an Adjuvant Treatment in Patients With Mild-to-Moderate Psoriasis… | Unifarco SpA new | |
| 2026-09-29 | NCT07846813 Evidencing Vibroacoustic Sensing for Inflammatory Skin Disease Monitoring | University of Edinburgh new | |
| 2026-09-25 | NCT07841314 Comparative Study on Unani Formulation Vs Active Control in Plaque Psoriasis | National Institute of Unani Medicine, Bengaluru new | Phase 2 |
| 2026-09-24 | NCT07839455 Oral and Topical Phytocannabinoids for Psoriasis | Federal University of Latin American Integration new | Phase 2 |
| 2026-09-23 | NCT07836283 Evaluation of the Efficacy and Safety of Bimekizumab (BZK) or Adalimumab (ADA) in the… | University Hospital, Rouen new | Phase 3 |
| 2026-09-14 | NCT07817394 Patient Study to Evaluate the Safety and Emollient Performance of Doublebase Once in the… | Dermal Laboratories Ltd new | |
| 2026-09-04 | NCT07804134 Skin-in-Sight: a Longitudinal Cohort Infrastructure for Standardized Remote Monitoring… | Medisch Spectrum Twente new | |
| 2026-09-03 | NCT07802964 A Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity… | Fujian Shengdi Pharmaceutical Co., Ltd. new | Phase 1 |
| 2026-08-28 | NCT07792928 A Study of HCXT-2001 Tablets and HCXT-2001 Tablets(A) in Healthy Adults | Shanghai Peptidstar Therapeutics Limited new | Phase 1 |
| Early Phase 1 | 5 | |
| Phase 1 | 25 | |
| Phase 1/2 | 3 | |
| Phase 2 | 42 | |
| Phase 2/3 | 5 | |
| Phase 3 | 70 | |
| Phase 4 | 47 |
| NCT ID | Title | Sponsor | Status | Updated |
|---|---|---|---|---|
| Phase 4 | ||||
| NCT07654751 | A Remotely Conducted Study to Assess Concentration of TREMFYA in Breast Milk of Lactating… | Janssen Research & Development, LLC | Recruiting | 2026-10-05 |
| NCT07725822 | An Open Label Trial to Evaluate Efficacy and Safety of Roflumilast 0.3% Cream for Chronic… | Modern Research Associates, PLLC | Recruiting | 2026-10-01 |
| NCT07487831 | The Impact of Salt Intake on Sodium in the Skin and Inflammatory Skin Disease | University of California, San Francisco | Recruiting | 2026-09-09 |
| NCT06857942 | A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation… | Eli Lilly and Company | Recruiting | 2026-09-04 |
| NCT07280702 | Deucravacitinib-TNFi Combination Therapy for Difficult-to-Control Psoriatic Disease | University of Texas Southwestern Medical Center | Recruiting | 2026-09-01 |
| NCT07141004 | A Study of Guselkumab Administered Subcutaneously in Treatment of Indian Participants… | Johnson & Johnson Private Limited | Recruiting | 2026-08-28 |
| NCT07111494 | Impact of Glucagon-like Peptide-1 (GLP-1) Analogs on Disease Outcomes in Psoriatic… | Medical College of Wisconsin | Recruiting | 2026-08-10 |
| NCT07087912 | Safety and Immunogenicity of the Live Attenuated Tetravalent Butantan-Dengue Vaccine in… | University of Sao Paulo General Hospital | Recruiting | 2026-07-20 |
| NCT05390515 | Psoriatic Immune Response to Tildrakizumab | University of California, San Francisco | Recruiting | 2026-06-04 |
| NCT05858632 | Immune Spatial Features of Guselkumab Cutaneous Response | University of California, San Francisco | Recruiting | 2026-06-04 |
| NCT05858645 | Correction of Psoriatic T Cell Signatures by Deucravacitinib | University of California, San Francisco | Recruiting | 2026-06-04 |
| NCT07611747 | Carotid Ultrasound-Based Strategy for Primary Prevention of Cardiovascular Events in… | Instituto de Investigación Marqués de Valdecilla | Recruiting | 2026-05-28 |
| NCT06454188 | A Study to Evaluate the Impact of Upadacitinib on Spondyloarthritis Outcomes in Patients… | CARE ARTHRITIS LTD. | Recruiting | 2026-04-03 |
| NCT05270733 | Development of Predictive Psoriasis Response Endotypes Using Single Cell Transcriptomics | University Hospitals Cleveland Medical Center | Recruiting | 2026-04-02 |
| NCT07503652 | Clinical Observation of Xeligekimab in the Treatment of Moderate to Severe Palmoplantar… | First Hospital of China Medical University | Recruiting | 2026-03-31 |
| NCT05004727 | Multi-Center PAMPA Study | NYU Langone Health | Recruiting | 2026-03-30 |
| NCT07486843 | Preventing Structural Damage in Early Psoriatic Arthritis | Chinese University of Hong Kong | Recruiting | 2026-03-23 |
| NCT06398106 | Proactive TDM Versus Standard Use of Biologics in Psoriasis | University Hospital, Ghent | Recruiting | 2026-03-04 |
| NCT07401992 | Effects of Semaglutide on Clinical Outcomes and Metabolic Inflammation in Psoriasis | Hospital Universitario Dr. Jose E. Gonzalez | Recruiting | 2026-02-11 |
| NCT07160231 | REDO-JAK: Dose Reduction of Janus Kinase Inhibitors in Patients With Inflammatory… | Sint Maartenskliniek | Recruiting | 2025-09-17 |
| NCT07149792 | A Multi-center RCT Clinical Trial on Personalized Precision Medicine for Patients With… | Taichung Veterans General Hospital | Recruiting | 2025-09-02 |
| NCT06974474 | Potential Role of Guselkumab in Modulating PAIN Perception and Related Gene Pathways: a… | Fondazione Policlinico Universitario Campus Bio-Medico | Recruiting | 2025-05-16 |
| NCT04537689 | Outcomes With Treatment and Withdraw of Ixekizumab in Patients With Plaque Psoriasis | Singapore General Hospital | Recruiting | 2022-11-25 |
| NCT04372277 | Taltz in Combination With Enstilar for Psoriasis | Psoriasis Treatment Center of Central New Jersey | Recruiting | 2020-05-04 |
| NCT04119102 | Duobrii in Combination With Biologics | Psoriasis Treatment Center of Central New Jersey | Recruiting | 2020-04-30 |
Bristol-Myers Squibb (17) · Janssen Research & Development, LLC (16) · AbbVie (10) · Assiut University (7) · Novartis Pharmaceuticals (7) · Second Affiliated Hospital, Zhejiang University, School of Medicine (7) · Takeda (7) · CorEvitas (6) · UCB Biopharma SRL (6) · University of California, San Francisco (6)